Entyvio Market Growth Potential: What The Latest Forecast Reveals
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Entyvio Market Size And Revenue Outlook Through 2030
Throughout the historical timeframe, the expansion witnessed can be credited to the shortcomings of traditional immunosuppressive treatments, the increasing occurrence of inflammatory bowel disease, the favorable clinical results observed with vedolizumab, the growing acceptance of biologics among gastroenterologists, and the regulatory clearances granted for ulcerative colitis and Crohn’s disease.
The growth in the forecast period is driven by the rising global prevalence of IBD, the expansion of treatments into earlier stages, improved diagnostic rates, greater access to biologic therapies, and an increased focus on long-term disease management.
Major trends anticipated in the forecast period include the increasing utilization of gut-selective biologic therapies, growing adoption in cases of moderate to severe IBD, a heightened preference for targeted integrin inhibition, the broadened use of long-term maintenance therapies, and an enhanced emphasis on safety compared to systemic immunosuppressants.
Get A Free Sample Report With In-Depth Market Insights:
Entyvio Market Industry Drivers: What’s Behind The Revenue Growth?
The rising occurrence of inflammatory bowel disease (IBD) is projected to drive expansion in the entyvio market in the future. IBD encompasses chronic, recurring inflammatory conditions affecting the gastrointestinal tract, marked by immune system imbalance that results in persistent inflammation and tissue harm. The growing frequency of IBD stems from various factors, including genetic susceptibility, environmental influences like diet and urban living, shifts in lifestyle leading to increased stress, and changes in gut microbiota due to aspects such as antibiotic consumption and less exposure to natural microorganisms. Entyvio offers a treatment for IBD by specifically targeting and inhibiting the alpha4beta7 integrin, thereby lessening the movement of inflammatory cells into the gut. For example, data from June 2024 by the Centre for Disease Control and Prevention, a US-based non-profit organization, indicated that the number of individuals with IBD in the United States is between 2.4 to 3.1 million people. Consequently, the rising prevalence of inflammatory bowel disease is stimulating the growth of the entyvio market.
Entyvio Market Segmentation And Category Overview
The entyvio market covered in this report is segmented –
1) By Route Of Administration: Subcutaneous Injection, Intravenous Infusion
2) By Treatment Line: First-Line Therapy, Second-Line Therapy
3) By Indication: Ulcerative Colitis (UC), Crohn’s Disease (CD)
4) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
#Entyvio Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies within the entyvio market are concentrating on developing maintenance therapies to enhance the long-term management of inflammatory bowel disease (IBD). Maintenance therapies are continuous treatments designed to control chronic conditions, prevent disease progression, and sustain a stable or improved health state after achieving initial therapeutic goals. These treatments aim to reduce the risk of relapses, complications, or symptoms over time, ensuring sustained disease control and a better quality of life for patients. For instance, in April 2024, Takeda pharmaceutical, a US-based pharmaceutical company, secured approval from the Food and Drug Administration, a US federal agency, for the subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after initial intravenous (IV) Entyvio induction therapy. The subcutaneous option permits self-administration using a pre-filled pen, making it more convenient for patients to manage their treatment at home following an initial IV infusion during the induction phase. Clinical studies have indicated that Entyvio significantly improves symptoms and induces remission in patients with Crohn’s disease when compared to a placebo.
Entyvio Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the entyvio market are Takeda Pharmaceutical Company Limited
View The Full Entyvio Market Report:
Entyvio Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the Entyvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the entyvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
